Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down - Here's Why

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report)'s stock price gapped down prior to trading on Friday . The stock had previously closed at $60.00, but opened at $57.23. Zealand Pharma A/S shares last traded at $57.23, with a volume of 100 shares traded.

Analysts Set New Price Targets

Separately, William Blair raised shares of Zealand Pharma A/S from a "hold" rating to a "strong-buy" rating in a research note on Friday, March 7th.

Zealand Pharma A/S Price Performance

The firm has a fifty day moving average of $66.33 and a two-hundred day moving average of $83.77. The company has a current ratio of 25.10, a quick ratio of 25.07 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $4.07 billion, a PE ratio of -23.00 and a beta of 0.74.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.67) earnings per share for the quarter, beating analysts' consensus estimates of ($0.77) by $0.10. Zealand Pharma A/S had a negative return on equity of 13.40% and a negative net margin of 2,127.09%. The firm had revenue of $1.14 million during the quarter, compared to analyst estimates of $248.61 million. Research analysts anticipate that Zealand Pharma A/S will post -2.19 EPS for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.